Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 30, 2015 4:59 PM ET

Biotechnology

Company Overview of Rigel Pharmaceuticals, Inc.

Company Overview

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders. It is developing fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and Phase II clinical trials for IgA nephropathy; R348, a topical JAK/SYK inhibitor that is in Phase II clinical trials for the treatment of dry eye in ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has a license agreement with AstraZen...

1180 Veterans Boulevard

South San Francisco, CA 94080

United States

Founded in 1996

127 Employees

Phone:

650-624-1100

Fax:

650-624-1101

Key Executives for Rigel Pharmaceuticals, Inc.

Chief Executive Officer, President, Director and Member of Finance Committee
Age: 54
Total Annual Compensation: $551.7K
Co-Founder, President of Discovery & Research, Executive Vice President and Director
Age: 66
Total Annual Compensation: $559.6K
Chief Financial Officer and Executive Vice President
Age: 45
Total Annual Compensation: $441.3K
Chief Medical Officer and Executive Vice President
Age: 67
Total Annual Compensation: $521.3K
Executive Vice President of Corporate Affairs, General Counsel and Corporate Secretary
Age: 50
Total Annual Compensation: $475.5K
Compensation as of Fiscal Year 2014.

Rigel Pharmaceuticals, Inc. Key Developments

Rigel Pharmaceuticals Mulls Acquisitions

Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL) is seeking acquisitions. Rigel Pharmaceuticals announced a follow-on equity offering in the amount of $30.00 million and said in prospectus, “We may also use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although we have no commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement.”

Rigel Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Rigel Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported contract revenues from collaborations of $5,184,000, which was all related to collaboration with Bristol-Myers Squibb. It was comprised of $4.8 million of amortization of the $30 million upfront payment and $350,000 of research reimbursement. Loss from operations was $13,974,000 compared with $25,456,000 for the same period a year ago. Net loss was $13,912,000 or $0.16 per basic and diluted share compared with $25,391,000 or $0.29 per basic and diluted share for the same period a year ago. For the six months, the company reported contract revenues from collaborations of $7,362,000. Loss from operations was $32,215,000 compared with $47,841,000 for the same period a year ago. Net loss was $32,105,000 or $0.36 per basic and diluted share compared with $47,694,000 or $0.54 per basic and diluted share for the same period a year ago.

Rigel Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 04, 2015

Rigel Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 04, 2015

Similar Private Companies By Industry

Company Name Region
AbbVie Biotherapeutics Inc. United States
Genus Oncology, LLC United States
Ravgen, Inc. United States
ViaCyte, Inc. United States
ReaMetrix, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Rigel Pharmaceuticals, Inc., please visit www.rigel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.